Formalizing drug indications on the road to therapeutic intent

Stuart J. Nelson, Tudor I. Oprea*, Oleg Ursu, Cristian G. Bologa, Amrapali Zaveri, Jayme Holmes, Jeremy J. Yang, Stephen L. Mathias, Subramani Mani, Mark S. Tuttle, Michel Dumontier

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)

Abstract

Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has 2 distinct indications, which differ solely on dosage strength. In progressing toward a practice of precision medicine, there is a need to capture and structure therapeutic intent for computational reuse, thus enabling more sophisticated decision-support tools and a possible mechanism for computer-aided drug repurposing. The indications for drugs, such as those expressed in the Structured Product Labels approved by the US Food and Drug Administration, appears to be a tractable area for developing an application ontology of therapeutic intent.
Original languageEnglish
Pages (from-to)1169-1172
Number of pages4
JournalJournal of the American Medical Informatics Association
Volume24
Issue number6
DOIs
Publication statusPublished - 1 Nov 2017

Keywords

  • therapeutic intent
  • drug indications
  • drug labels

Cite this